Friday, February 24, 2023

​​

7:00 – 8:00 AM

Breakfast

​

8:00 – 9:35 AM Session III

Biomarkers of alpha-1 antitrypsin (AAT) deficiency related liver disease (LD)

Moderated by: Pavel Strnad, MD and Mark Brantly, MD

​

8:00 – 8:15 AM         

AI based assessment of liver pathology in AAT

Janani Iyer, PhD (PATH AI)

8:15 – 8:30 AM

MRI imaging-based biomarkers of AAT deficiency related LD

Veeral Ajmera, MD

​

8:30 – 8:45 AM       

Recent updates from AAT LD: three-center prospective study

Jeffrey Teckman, MD

​

8:45 – 9:00 AM      

Should we screen all patients with ZZ lung disease for liver disease? How should they be screened and what are the opportunities for collaboration with the biomarker consortium?

Jeanine D'Armiento, MD

​

9:00 – 9:15 AM

How to set up collaboration between a pulmonary clinic and a liver clinic

Ginger Clark, MD

​

9:15 – 9:35 AM

Panel discussion and Q&A

9:35 – 10:00 AM

Break and poster viewing

10:00 – 11:30 AM Session IV

Emerging therapies and clinical drug development endpoints

Moderated by: Alice Turner, MBChB (Hons), MRCP, PGCE (MedEd), PhD and Aleksander Krag, MD

​

10:00 – 10:15 AM     

How to assess pulmonary safety of IP in an AAT LD trial: issues and proposed solutions

Mark Brantly, MD

​

10:15 – 10:30 AM     

How to engage the FDA and EMA regulatory pathways for clinical drug development in AAT deficiency related LD

Rohit Loomba, MD, MHSc

10:30 – 10:45 AM       

Real world experience: why, when, and how? What can we learn from other disease areas?

Michael Fried, MD

​

10:45 – 11:00 AM   

Economic burden and patient reported outcome assessment in AAT deficiency related LD

Zobair Younossi, MD, MPH

​

11:00 – 11:15 AM

Role of AASLD, EASL, and societies in building consensus

Aleksander Krag, MD

​

11:15 – 11:30 AM

Concluding remarks for the open session

Rohit Loomba, MD, MHSc

​

11:30 AM – 12:15 PM

Break and lunch

​

12:15 PM

Meeting concludes